<?xml version='1.0' encoding='utf-8'?>
<document id="30431448"><sentence text="Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses."><entity charOffset="39-49" id="DDI-PubMed.30431448.s1.e0" text="dabigatran" /><entity charOffset="54-63" id="DDI-PubMed.30431448.s1.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.30431448.s1.e0" e2="DDI-PubMed.30431448.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30431448.s1.e0" e2="DDI-PubMed.30431448.s1.e1" /></sentence><sentence text=": Dabigatran is a direct thrombin inhibitor that was approved as an alternative to warfarin because it offers the benefit of predictable pharmacokinetic properties, favorable safety profile and ease of administration"><entity charOffset="2-12" id="DDI-PubMed.30431448.s2.e0" text="Dabigatran" /></sentence><sentence text=" Despite the improved safety profile, dabigatran use can lead to bleeding events"><entity charOffset="38-48" id="DDI-PubMed.30431448.s3.e0" text="dabigatran" /></sentence><sentence text=" The bleeding risk associated with dabigatran is higher in the setting of renal impairment or drug-drug interactions resulting in supratherapeutic serum concentrations"><entity charOffset="35-45" id="DDI-PubMed.30431448.s4.e0" text="dabigatran" /></sentence><sentence text=" Unfortunately, clinically significant interactions are not always identified by providers, especially in the case of infrequent drug-drug combinations" /><sentence text=" Dabigatran-related coagulopathy can be effectively reversed by idarucizumab"><entity charOffset="1-11" id="DDI-PubMed.30431448.s6.e0" text="Dabigatran" /></sentence><sentence text=" However, high dabigatran serum concentrations can lead to increased tissue distribution resulting in decreased idarucizumab efficacy and repeat idarucizumab doses may be warranted"><entity charOffset="15-25" id="DDI-PubMed.30431448.s7.e0" text="dabigatran" /></sentence><sentence text=" This case describes a patient presenting with uncontrolled bleeding due to a significant drug-drug interaction between quinidine and dabigatran resulting in acute kidney injury and persistent coagulopathy despite multiple idarucizumab doses and transfusion measures"><entity charOffset="120-129" id="DDI-PubMed.30431448.s8.e0" text="quinidine" /><entity charOffset="134-144" id="DDI-PubMed.30431448.s8.e1" text="dabigatran" /><pair ddi="false" e1="DDI-PubMed.30431448.s8.e0" e2="DDI-PubMed.30431448.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30431448.s8.e0" e2="DDI-PubMed.30431448.s8.e1" /></sentence><sentence text="" /></document>